Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have earned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $43.25.

Several equities analysts have commented on ARWR shares. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They set a “neutral” rating and a $31.00 price objective for the company. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 16th. Morgan Stanley reduced their price objective on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $28.19 on Friday. Arrowhead Pharmaceuticals has a 52-week low of $20.67 and a 52-week high of $39.83. The stock has a market capitalization of $3.50 billion, a price-to-earnings ratio of -6.63 and a beta of 0.94. The company’s 50 day moving average price is $25.87 and its 200-day moving average price is $27.90.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative return on equity of 140.72% and a negative net margin of 163.32%. During the same quarter in the prior year, the firm posted $0.45 earnings per share. The firm’s revenue for the quarter was down 100.0% on a year-over-year basis. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -3.04 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director Victoria Vakiener sold 1,799 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the sale, the director now directly owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Arrowhead Pharmaceuticals news, insider Tracie Oliver sold 9,394 shares of the company’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total value of $237,480.32. Following the transaction, the insider now owns 127,107 shares of the company’s stock, valued at approximately $3,213,264.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Victoria Vakiener sold 1,799 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the transaction, the director now directly owns 30,205 shares in the company, valued at approximately $704,078.55. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Fifth Third Bancorp grew its position in shares of Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares in the last quarter. Van ECK Associates Corp lifted its stake in shares of Arrowhead Pharmaceuticals by 22.9% during the 4th quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 447 shares during the last quarter. Washington Trust Advisors Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $25,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Arrowhead Pharmaceuticals by 12.3% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 952 shares during the last quarter. Finally, Securian Asset Management Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 12.5% during the 1st quarter. Securian Asset Management Inc. now owns 10,100 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 1,121 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.